Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

GLOBEIMMUNE INC (GBIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/23/2017 D Form D - Notice of Exempt Offering of Securities
07/25/2016 15-12B Form 15-12B - Securities registration termination [Section 12(b)]
07/15/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
07/15/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
07/15/2016 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities
07/05/2016 8-K Quarterly results
05/19/2016 8-K Form 8-K - Current report
05/12/2016 8-K Form 8-K - Current report
05/11/2016 10-Q Quarterly Report for the period ended March 31, 2016
04/28/2016 10-K/A Annual Report for the period ended December 31, 2015 [amend]
03/16/2016 8-K Form 8-K - Current report
03/15/2016 10-K Annual Report for the period ended December 31, 2015
02/24/2016 SC 13G Bartelt Jeffrey W reports a 5.2% stake in GlobeImmune, Inc.
02/23/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement by and between GlobeImmune, Inc. and Timothy C. Rodell"
02/16/2016 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 11.4% stake in GlobeImmune, Inc.
02/12/2016 SC 13G Sequel Limited Partnership III reports a 5.9% stake in GlobeImmune, Inc. Address of
02/12/2016 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2016 8-K Other Events
11/13/2015 8-K Quarterly results
Docs: "GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights"
11/12/2015 10-Q Quarterly Report for the period ended September 30, 2015
08/14/2015 8-K Quarterly results
Docs: "GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights"
08/13/2015 10-Q Quarterly Report for the period ended June 30, 2015
08/04/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy"
07/17/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/13/2015 8-K Submission of Matters to a Vote of Security Holders
06/11/2015 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits
Docs: "GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring"
05/27/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "GlobeImmune Announces Top Line Results from GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients"
05/22/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/22/2015 DEF 14A Form DEF 14A - Other definitive proxy statements
05/14/2015 8-K Quarterly results
Docs: "GlobeImmune Announces First Quarter 2015 Results and Corporate Highlights"
05/13/2015 10-Q Quarterly Report for the period ended March 31, 2015
04/29/2015 10-K/A Annual Report for the period ended December 31, 2014 [amend]
04/22/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute"
04/02/2015 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from KPMG LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy